Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoosier Cancer Research Network
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoosier Cancer Research Network
Dana-Farber Cancer Institute
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center
NRG Oncology
Mayo Clinic
National Cancer Institute (NCI)
Fox Chase Cancer Center
University of Pittsburgh
ImmuneSensor Therapeutics Inc.
The Netherlands Cancer Institute
Goethe University
Memorial Sloan Kettering Cancer Center
Ontario Clinical Oncology Group (OCOG)
Vanderbilt-Ingram Cancer Center
Royal Marsden NHS Foundation Trust
Swiss Cancer Institute
Columbia University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
University of California, San Diego
Hoosier Cancer Research Network
University of Michigan Rogel Cancer Center
Case Comprehensive Cancer Center
UNICANCER
University Hospital, Ghent
Consorzio Oncotech
Jules Bordet Institute
Bristol-Myers Squibb
AIO-Studien-gGmbH
University College, London
Duke University
Bristol-Myers Squibb
Bristol-Myers Squibb
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
UNICANCER
AIO-Studien-gGmbH
Kidney Cancer Research Bureau
MultiVir, Inc.
Medical University of South Carolina
University of Kansas Medical Center